Prospective Evaluation of a New Molecular Tool for Early Diagnosis of Mucormycosis — MODIMUCOR  

Mucormycosis Clinical Trial

Official title: Prospective Evaluation of a New Molecular Tool for Early Diagnosis of Mucormycosis

Status Completed

Clinical Trial Summary

This Study evaluates the performance (sensitivity, specificity, positive and negative predictive value values and likelihood ratios) of the DNA detection test for the diagnosis of mucormycosis by comparing it to the routine tests such as CT scan aspects, histopathology, microscopy and fungal culture, in a test group of 52 patients including :

• patients at high-risk according to the EORTC/MSG criteria (patients with prolonged severe neutropenia, receiving corticosteroids or T-cell suppressors, recipients of allogeneic HSCT, or inherited severe immunodeficiency),

• patients with other predisposing factors of invasive mould disease ( diabetes, AIDS, haematological malignancies or solid tumours, trauma, burns); Patients already diagnosed with probable or proven mucormycosis irrespective of underlying conditions.

Clinical Trial Description

The patients eligible for this study will already be hospitalized with repeated monitoring of clinical and biological parameters.

Participation in the study will result in an additional sampling of blood (estimated volume 6 mL for each sampling) on day of suspicion of the mucormycosis and then twice a week up to a maximum of 8 weeks.

vials will be added to the routine sampling of these patients (ie, at the time of routine sampling for galactomannan antigemia), and no new sampling procedure will be required. ;

Related Conditions & MeSH terms

• Mucormycosis
• Zygomycosis

• NCT number: NCT02845934
• Study type: Interventional
• Source: Centre Hospitalier Universitaire de Besancon
• Status: Completed
• Phase: N/A
• Start date: January 2014
• Completion date: January 2018